Skip to main content

Stepping up from ICS/LABA to FF/UMEC/VI in Patients with Uncontrolled Asthma: Outcomes from the 52-Week PERFORM Pragmatic Randomized Controlled Trial

In brief

Triple inhaler improved lung function by 67 mL at one year

Among adults with uncontrolled asthma already using an inhaled steroid and long-acting bronchodilator, stepping up to fluticasone furoate/umeclidinium/vilanterol improved lung function by 67 mL more than usual care at 52 weeks. Patients were also more likely to achieve better asthma control and clinical remission, with no unexpected safety findings; the remission analysis was not adjusted for multiple comparisons.

Journal
Advances in therapy (Q1)
Published
16 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
John J Oppenheimer, Erika Penz, Alan P Baptist, Gabriel Garcia, Hiroyuki Nagase, Amila Poddar, et al.
PMID
43037944
DOI
10.1007/s12325-026-03860-5

Why clinicians should know about it

  • Picked for Pulmonary and Respiratory Medicine (paper of the day, 17 November 2026): Pragmatic randomized trial of triple-inhaler escalation for uncontrolled asthma
  • Picked for Family Practice (paper of the day, 17 November 2026): Pragmatic trial tests escalation for uncontrolled asthma in adults

Abstract

INTRODUCTION: Asthma remains uncontrolled in many patients receiving inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), suggesting that guideline-recommended escalation to triple therapy is often delayed. We report outcomes in patients with uncontrolled, infrequently exacerbating asthma (understudied in traditional randomized controlled trials) stepping up from ICS/LABA to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) from the PERFORM trial. METHODS: PERFORM, a randomized, open-label, active-controlled, pragmatic trial in symptomatic adults with uncontrolled, infrequently exacerbating asthma, evaluated the effectiveness and safety of FF/UMEC/VI versus usual care ICS/LABA. Outcomes included trough forced expiratory volume in 1 s (FEV1), asthma control (Asthma Control Questionnaire [ACQ-5/-6/-7]), and achieving clinical remission at Week 52 for the step-up (participants treated with ICS/LABA pre-randomization) and overall population. Safety was assessed throughout the study. RESULTS: Overall, 783 of 1236 participants in PERFORM received ICS/LABA pre-randomization, with 392 and 391 randomized to FF/UMEC/VI and ICS/LABA, respectively. Statistically significant improvements in trough FEV1 were observed for FF/UMEC/VI versus ICS/LABA at Week 24 and were durable to Week 52 (least squares means treatment difference in change from baseline [95% confidence interval (CI)]: 66 ml [29, 103] and 67 ml [28, 106] at Weeks 24 and 52). FF/UMEC/VI showed greater odds of achieving ≥ 0.5-point improvement from baseline in ACQ-7 total score at Week 24 and achieving clinical remission at Week 52 versus ICS/LABA (adjusted odds ratio [95% CI]: 1.54 [1.12, 2.12] and 2.78 [1.82, 4.24]; not multiplicity adjusted). Results (including the Week 52 safety profile) were similar to the overall PERFORM population. CONCLUSION: Escalation to FF/UMEC/VI from ICS/LABA improved lung function, asthma control, and clinical remission, with no unexpected safety findings versus usual care ICS/LABA at Weeks 24 and 52, consistent with the overall PERFORM population. Initiation with FF/UMEC/VI may address the unmet need for optimized treatment in patients with uncontrolled, infrequently exacerbating asthma. TRIAL REGISTRATION: GSK ID: 219912/NCT06372496. Supplementary file1 (MP4 149035 KB).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.